

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7980007

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ERIC A. APPEL	06/21/2022
JOSEPH L. MANN	06/22/2022
JOHN KLICH	06/21/2022
CATHERINE M. KASSE	06/22/2022
RECEIVING PARTY DATA	
Name:	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Street Address:	BUILDING 170, THIRD FLOOR, MAIN QUAD
Internal Address:	P.O. BOX 20386
City:	STANFORD
State/Country:	CALIFORNIA
Postal Code:	94035-2038
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	18200958
PCT Number:	US2323257
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8587242450
Email:	docketing@mdiplaw.net
Correspondent Name:	TORREY PINES LAW GROUP PC
Address Line 1:	12636 HIGH BLUFF DRIVE
Address Line 2:	SUITE 400
Address Line 4:	SAN DIEGO, CALIFORNIA 92130
ATTORNEY DOCKET NUMBER:	STNFD.022-061US
NAME OF SUBMITTER:	CYNTHIA A. WILLIS
SIGNATURE:	/Cynthia A. Willis/
DATE SIGNED:	05/31/2023

Total Attachments: 6

source=STNFD.22-061 fully executed combined Assignment and Declaration_#page1.tif
source=STNFD.22-061 fully executed combined Assignment and Declaration_#page2.tif
source=STNFD.22-061 fully executed combined Assignment and Declaration_#page3.tif
source=STNFD.22-061 fully executed combined Assignment and Declaration_#page4.tif
source=STNFD.22-061 fully executed combined Assignment and Declaration_#page5.tif
source=STNFD.22-061 fully executed combined Assignment and Declaration_#page6.tif

COMBINED ASSIGNMENT AND DECLARATION

Attorney Docket No.: STNFD.22-061P2
Stanford Docket No.: S22-061

WHEREAS Eric A. APPEL of Palo Alto, CA; Joseph L. MANN of Mountain View, CA; John KLICH of Freehold, NJ, and Catherine M. KASSE of Menlo Park, CA are the inventor(s) of an invention entitled "ANTIBODY BIOPHARMACEUTICAL FORMULATIONS INCLUDING POLYMER EXCIPIENTS" that is the subject matter of: (check all that apply);

- ☒ a provisional application for Letters Patent which is identifiable in the United States Patent and Trademark Office by Application No. 63/344,927 filed on May 23, 2022;
- ☒ an application for Letters Patent which is identifiable in the United States Patent and Trademark Office by Application No. 18/200,958 filed on May 23, 2023 and/or executed on even date herewith; and
- ☒ an international application for Letters Patent filed pursuant to the Patent Cooperation Treaty which is identifiable in the United States Patent and Trademark Office by Application No. PCT/US2023/023257 filed on May 23, 2023 and/or executed on even date herewith;


WHEREAS, The Board of Trustees of the Leland Stanford Junior University, a trust with corporate powers under the laws of the State of California and the United States of America, and having offices at Building 170, Third Floor, Main Quad, P.O. Box 20386, Stanford, CA 94035-2038 USA, ("Assignee") is desirous of acquiring the entire right, title, and interest in and to the invention, the applications, and any and all Letters Patent or similar foreign or domestic legal protection;

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I transfer to Assignee, its successors and assigns, my entire right, title, and interest in and to the invention, the above-identified applications, the right to claim priority, all provisional applications from which any of the above-identified applications claim priority, corresponding domestic and foreign applications, any continuation, division, renewal, or substitute for the applications, all Letters Patent, any reissue, re-examination, or similar legal protection issuing related to the Letters Patent, and all rights and benefits under any applicable treaty or convention; and I authorize the Director of the United States Patent and Trademark Office or foreign equivalent to issue the Letters Patent or similar legal protection to the Assignee.

I authorize the Assignee, its successors and assigns, to insert in this instrument the filing date(s) and application numbers when ascertained. I further authorize the Assignee, its successors and assigns, or anyone it may properly designate, to apply for Letters Patent or similar legal protection, in its own name if desired, in any and all foreign countries, and appoint Assignee the common representative in the above identified international application and any international application for the invention.

I represent to the Assignee, its successors, and assigns, that I have not and shall not execute any writing or do any act whatsoever conflicting with this Assignment. I, my executors or administrators, will at any time upon request, without additional consideration, but at the expense of the Assignee, its successors and assigns, execute and deliver to Assignee or its legal representatives such additional writings and do such additional acts as the Assignee, its successors and assigns, may deem desirable to perfect its enjoyment of this grant, and render all assistance in making application for and obtaining, maintaining, and enforcing the Letters Patent or similar legal protection on the invention in any and all countries, including without limitation providing testimony in any related interference, litigation, or proceeding.

The above-identified application was made or authorized to be made by me. I believe that I am the original inventor or an original joint inventor of a claimed invention in the application. I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both. I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in- part application.



Eric A. APPEL

6-21-22

Date

Joseph L. MANN

Date


John KLICH

6-21-22

Date


Catherine M. KASSE

Date

The above-identified application was made or authorized to be made by me. I believe that I am the original inventor or an original joint inventor of a claimed invention in the application. I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both. I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in- part application.

Eric A. APPEL

Date



Joseph L. MANN

6/22/2022

Date

John KLICH

Date

Catherine M. KASSE

Date

The above-identified application was made or authorized to be made by me. I believe that I am the original inventor or an original joint inventor of a claimed invention in the application. I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both. I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in- part application.

Eric A. APPEL


Date

Joseph L. MANN

Date

John KLICH

Date



Catherine M. KASSE

06/22/2022

Date

Attorney Docket No.: STNFD.22-061P2
Stanford Docket No.: S22-061

SIGNED FOR AND ON BEHALF OF THE ASSIGNEE,
The Board of Trustees of The Leland Stanford Junior University

June 30, 2022
Date


Signature

Justin Zahrt
Name

Assistant Director, Intellectual Property
Position



STANFORD UNIVERSITY • OFFICE OF TECHNOLOGY LICENSING

3000 EL CAMINO REAL • BUILDING FIVE SUITE 300 • PALO ALTO CA 94306-2100
(650) 723-0651 • FAX (650) 725-7295

KARIN H. IMMERGLUCK
EXECUTIVE DIRECTOR
OFFICE OF TECHNOLOGY LICENSING

TO: Justin Zahrt

FROM: Karin Immergluck
Executive Director

DATE: March 9, 2020

RE: DELEGATION OF SIGNATURE AUTHORITY: Assistant Director, Intellectual
Property, Office of Technology Licensing

Pursuant to the Delegation of Signature Authority from the Vice Provost and Dean of Research to me as Executive Director by memorandum dated June 4, 2018, I hereby further delegate Signature Authority for transactions specified below to the Assistant Director, Intellectual Property. The Assistant Director, Intellectual Property, has the authority to sign documents or approve transactions relating to the filing, prosecution, registration and maintenance of intellectual property assets of Stanford University, including patent applications, patents, copyright works, and trademarks. This authority includes the powers to sign and certify official intellectual property-related government and patent office documents, including power of attorney documents and intellectual property assignment documents on behalf of the University as the assignee.

Even though the authority may exist to sign documents, custom, sound business practice and judgement, as well as the involvement of any novel legal issues or potentially significant legal exposure, should result in bringing matters of significant policy, budget, or legal impact to the attention of the Executive Director, and in the case of legal impact, to the Office of General Counsel, for approval. The authority granted here is not a substitute for compliance with existing University policies.

This Signature Authority may not be further delegated without the approval and further delegation from the Executive Director.

All delegations of Signature Authority must be filed with the Vice Provost and Dean of Research and the Office of General Counsel.

Karin H. Immergluck
Executive Director
Office of Technology Licensing